NDA 212895 · Cspc Ouyi
Conjupri
Levamlodipine Maleate · Oral
DiscontinuedLast checked: Nov 19, 2026Latest source record: Dec 19, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Dec 19, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
34
9 Phase 3, 0 recruiting
FAERS reports
125
119 serious, 14 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 11, 2024.
CONJUPRI ® is calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. 1.1 Hypertension CONJUPRI ® is indicated for the treatment of hypertension in adults and patients 6 years and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including levamlodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but...
Mechanism: Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 19, 2019 Original approval · Type 2 - New Active Ingredient and Type 3 - New Dosage Form LabelLetterReview
3 products under this application
- CONJUPRI · LEVAMLODIPINE MALEATE EQ 2.5MG BASE · TABLET, ORAL · Discontinued
- CONJUPRI · LEVAMLODIPINE MALEATE EQ 5MG BASE · TABLET, ORAL · Discontinued
- CONJUPRI · LEVAMLODIPINE MALEATE EQ 1.25MG BASE · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Levamlodipine" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential HypertensionPivotal-lookingCompleted
Jiangsu Simcere Pharmaceutical Co., Ltd.Industry
NCT01131546 · 1,080 participants (planned) · Start Dec 2009 · Primary completion Mar 2011
Drug: Levamlodipine besylate; Amlodipine maleate · For: Essential Hypertension
Sites: Beijing, China
- A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive PatientsPivotal-lookingNot yet recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT06771245 · 606 participants (planned) · Start Jan 24, 2025 · Primary completion Mar 30, 2026
Drug: SYH9056; Levamlodipine and 4 more · For: Mild-to-moderate Essential Hypertension
- CKD-828 Primary Hypertension Trial(Dose-selection)Pivotal-lookingCompleted
Chong Kun Dang PharmaceuticalIndustry
NCT01128322 · 430 participants (planned) · Start Jul 2010 · Primary completion Mar 2011
Drug: S-Amlodipine, Telmisartan; S-Amlodipine and 2 more · For: Hypertension
Sites: Anyang, South Korea; Bucheon-si, South Korea; Busan, South Korea · 26 sites in all
- A Clinical Study Comparing Ankle Swelling Caused by Two Different Blood Pressure Medications, Levamlodipine and Amlodipine, in Post-menopausal Women With Mild High Blood Pressure.Pivotal-lookingNot yet recruiting
Zentiva, k.s.Industry
NCT07618806 · 344 participants (planned) · Start Nov 30, 2026 · Primary completion Dec 31, 2027
Drug: Amlodipine · For: Hypertension; Oedema
- The Efficacy of a Combination of Telmisartan/S-Amlodipine Compared With Telmisartan MonotherapyPivotal-lookingCompleted
Chong Kun Dang PharmaceuticalIndustry
NCT02231788 · 217 participants · Start Jun 2014 · Primary completion Mar 2018
Drug: Telminuvo®Tab. 40/2.5mg; Telmitrend®Tab. 80mg · For: Hypertension
Sites: Gyeonggi-do, South Korea; Jeju City, South Korea; Seongnam, South Korea · 11 sites in all
- Efficacy of a Telmisartan/S-Amlodipine on 24-hour BP Control in Hypertensive Patients Inadequately ControlledPivotal-lookingStatus unknown
Chong Kun Dang PharmaceuticalIndustry
NCT02526875 · 208 participants (planned) · Start Apr 2015 · Primary completion Nov 2017
Drug: Telminuvo®Tab. 40/2.5mg · For: Hypertension
Sites: Seoul, South Korea; Goyang, South Korea; Goyang-si, South Korea · 10 sites in all
- Anti Inflammatory Treatment of HypertensionPivotal-lookingCompleted
Affiliated Hospital of North Sichuan Medical CollegeAcademic, hospital or other
NCT04740840 · 200 participants · Start May 1, 2010 · Primary completion Apr 2, 2012
Drug: Levamlodipine; Amlodipine · For: Hypertension
- Efficacy and Safety of TELMINUVO to Stage 2 HypertensionPivotal-lookingStatus unknown
Chong Kun Dang PharmaceuticalIndustry
NCT01983735 · 200 participants (planned) · Start Jan 2014 · Primary completion Aug 2014
Drug: TELMINUVO Tab. (80/2.5mg); TELMINUVO Tab. (80/5mg) and 2 more · For: Hypertension
Sites: Seoul, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea12
- fatigue8
- hypertension8
- nausea8
- pain8
- arthralgia7
- drug ineffective7
- hypoaesthesia7
- malaise7
- pneumonia7
- constipation6
- decreased appetite6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 2 |
| 2013 | 5 |
| 2014 | 10 |
| 2015 | 1 |
| 2016 | 10 |
| 2017 | 10 |
| 2018 | 20 |
| 2019 | 11 |
| 2020 | 9 |
| 2021 | 10 |
| 2022 | 8 |
| 2023 | 9 |
| 2024 | 5 |
| 2025 | 9 |
| 2026 | 6 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Randomized, two-way crossover bioequivalence study of levamlodipine besylate tablets in healthy Chinese subjects߭.
Xu SM, Wang YL, Li D, et al. · Int J Clin Pharmacol Ther 2017 · Clinical Trial, Phase I, Randomized Controlled Trial
- Effects of antihypertensive drugs losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension combined with isolated impaired fasting glucose.
Xiao WY, Ning N, Tan MH, et al. · Hypertens Res 2016 · Randomized Controlled Trial
- Effect of administration of low-dose irbesartan and hydrochlorothiazide combined with levamlodipine at different times on the circadian rhythm of blood pressure and the levels of MMPs and TIMPs in non-dipper patients with grade 1 and 2 hypertension.
Yan P, Luo Y, Zhang J, et al. · J Clin Hypertens (Greenwich) 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Comparative effects of 2.5mg levamlodipine and 5mg amlodipine on vascular endothelial function and atherosclerosis.
Lu Y, Yin J, Wu X, et al. · Pak J Pharm Sci 2019 · Randomized Controlled Trial
- Bioequivalence of levamlodipine besylate tablets in healthy Chinese subjects: a single-dose and two-period crossover randomized study.
Li X, Wang C, Li T, et al. · BMC Pharmacol Toxicol 2020 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy and Safety of Dihydropyridine Calcium Channel Blockers for Primary Hypertension: A Bayesian Network Meta-analysis.
Wang H, Yang H, Zhang Z, et al. · Curr Hypertens Rev 2025 · Network Meta-Analysis
Sponsor: Cspc Ouyi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.